Luminor Medical Technologies Acquiring Exclusive Canadian & Jamaican Licenses for Cannabis Products – Video Available on Investmentpitch.com May 12, 2017
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) May 12, 2017
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) May 9, 2017 Energy
DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma (“GBM”) at ASCO Annual Meeting Apr 28, 2017 Others
DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme Apr 26, 2017 Others
DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 22, 2017 Others
